The FDA approved Emcitate, a tablet for oral suspension containing the thyroid hormone analogue tiratricol, on Sept. 28 for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency. It is the first therapy the agency has cleared for the disorder, which is also known as Allan-Herndon-Dudley syndrome.
The approval is narrower than the phrase "first treatment" suggests, and the difference is the story. The agency cleared a drug for one part of a two-part disease. The label asks physicians to monitor it with a laboratory method most hospitals do not run. And the molecule it contains spent the last years of the 1990s in the supplement aisle, sold for weight loss, until the FDA told consumers to stop taking it.
A transporter that no longer works
MCT8 deficiency is caused by pathogenic variants in the gene for the MCT8 transporter, the protein that carries thyroid hormone across the blood-brain barrier. When the transporter does not work, the brain receives too little thyroid hormone while triiodothyronine, or T3, builds up in the bloodstream.
That produces two problems at once. Patients have profound intellectual and motor disability; many cannot sit or walk independently, and speech is absent or severely limited. Their bodies run on an excess of thyroid hormone, with a rapid heart rate, elevated blood pressure and the metabolic strain that comes with both. The disorder is X-linked and affects mostly boys. Egetis Therapeutics, the Swedish company that developed the drug, reports a median life expectancy of about 35 years.
Tiratricol is a thyroid hormone analogue that enters cells without the transporter that MCT8 deficiency disables, which is what makes it useful here. "Patients living with MCT8 deficiency and their families had no FDA-approved treatment option," said Marina Zemskova, deputy director of the Division of General Endocrinology at the FDA's Center for Drug Evaluation and Research.
The trial randomized 15 patients for 30 days
The study supporting approval is called ReTRIACt. It began with 20 male patients aged 5 to 31 in a run-in period while their doses were adjusted. The 15 who reached a stable dose were then randomly assigned to keep taking tiratricol or switch to a placebo for 30 days.
The first primary endpoint was the ratio of the rate of change in total T3, and continued treatment won it: 1.5, with a 95 percent confidence interval of 1.0 to 2.2 and a p-value of .034, a result whose lower bound sits exactly on the line between an effect and none. Mean total T3 rose 64.6 ng/dL on placebo and fell 0.2 ng/dL on tiratricol, and every patient given placebo recorded a larger rise than any patient who stayed on the drug.
The second primary endpoint was the share of patients whose total T3 rose above the upper limit of normal, the threshold for rescue treatment. Four of the eight placebo patients met it, against one of seven on tiratricol, a patient who discontinued early and was counted as meeting it. The confidence interval for that difference crossed zero, which means the trial could not rule out no difference between the groups.
The longer-term figures come from a 12-month, open-label study of 46 male patients ranging in age from 10 months to 66.8 years. Mean total T3 fell from 323.4 ng/dL to 118.3 ng/dL. Mean resting heart rate dropped 8.9 beats per minute and mean systolic blood pressure fell 4.1 mm Hg. That study had no comparison group, so those numbers describe what happened to patients on treatment rather than what the drug did.
Both studies measure the hormone, not the development. The trial that carries the approval is small, short, and built to show that withdrawing the drug makes T3 rise again. It does not measure whether a patient walks, speaks, or lives longer.
The label sends doctors to a test few laboratories offer
Tiratricol cross-reacts with the immunoassays most clinical laboratories use to measure T3, and the reaction makes a patient's total T3 read higher than it is. The label therefore directs clinicians to measure total T3 by liquid chromatography tandem mass spectrometry. No FDA-authorized test of that kind for total T3 is currently available, according to pharmacy trade coverage of the prescribing information, which leaves each laboratory to verify its own method before anyone interprets a result.
The problem is not new to the people who treat thyroid disease. In February 2000, the American Thyroid Association endorsed an FDA warning about a weight-loss supplement called Triax Metabolic Accelerator, and one of the reasons it gave for backing the warning was that T3 and the supplement's active ingredient, TRIAC, cross-react in most assays. TRIAC is another name for tiratricol. The interference that concerned the association in 2000 is written into the label as a monitoring instruction in 2026.
Because tiratricol is a hormone analogue, the rest of the label reads like a warning label's. Signs of thyrotoxicosis, including a fast heart rate, elevated blood pressure, diarrhea and excessive sweating, can appear while the dose is being adjusted. The drug is tapered rather than stopped abruptly, and it is not to be combined with other thyroid medications such as levothyroxine, with bile acid sequestrants, or with psychostimulants.
The molecule's earlier life in the supplement aisle
Before it was a prescription drug with a monitoring protocol, tiratricol was a diet pill.
In November 1999, the FDA warned consumers not to take Triax Metabolic Accelerator, a product sold as a dietary supplement. The agency's concern, as the American Thyroid Association described it the following February, was that the active ingredient was a potent thyroid hormone rather than a nutrient, and that the doses on the label could push users into thyrotoxicosis. The association put numbers to it: TRIAC is a metabolite of thyroid hormone in humans, roughly 5 percent as potent as thyroxine, so 1,000 micrograms of TRIAC taken by mouth is about equivalent to 50 micrograms of thyroxine. The supplement's recommended dose was 2,000 to 4,000 micrograms a day, the equivalent of 100 to 200 micrograms of thyroxine, and the association warned that bone and liver appeared more sensitive to it than other organs.
"TRIAC should not be used to accelerate weight loss," the statement concluded.
The approved drug is a fraction of the dose that produced that warning. Starting doses are 175 micrograms a day for patients weighing 10 kilograms or less and 350 micrograms a day for heavier patients, titrated upward only until total T3 falls below the midpoint of the normal range for the patient's age. The label still carries a boxed warning stating that the drug is not for the treatment of obesity or for weight loss, a reminder that the molecule's most widespread use was the one nothing in the approval supports.
What taking it involves
The tablets are dispersed in room-temperature drinking water in a 10- to 12-milliliter syringe and given by mouth or through an enteral feeding tube. They are not to be swallowed whole, chewed or crushed, and any suspension not used within 30 minutes is discarded. Tablets, including split halves, need refrigeration and protection from light. Doses are adjusted about every two weeks. The most common adverse reactions in the trials were diarrhea, vomiting, rash and hyperhidrosis, the clinical term for excessive sweating.
Egetis said it expects the drug to be commercially available in the United States in eight to 10 weeks, distributed through the specialty pharmacy PANTHERx Rare and the company's RareLink patient support program. The FDA's announcement lists the designations attached to the application: orphan drug, rare pediatric disease, fast track, breakthrough therapy and priority review. Egetis also said it received a rare pediatric disease priority review voucher and intends to sell it in the fourth quarter, a common route for a small company to turn an approval into cash without parting with the drug.
What the approval leaves open
The indication is peripheral thyrotoxicosis, not the neurodevelopmental disorder that gives the condition its name in most families' experience. The distinction is deliberate, and the label states the narrow version: the drug is approved to treat the hormone excess, with no claim about cognition, development or survival.
Pareto, the investment bank that rates Egetis a sell, made the same point in a note reported by the Swedish financial news service Direkt. The bank wrote that the U.S. prescribing information is as narrow as the European one, and that the approval was never the basis of its rating. It estimated the U.S. patient population at about 60 people in the drug's early access program and just over 100 identified in total, said it had carried an 80 percent probability of approval in its base case, and noted that it had seen no significant sales in Germany, where the drug launched after European approval in 2025.
That the approval was expected does not make it small for the families who have been waiting for one. It does mean the two readings of the news begin from different questions: whether a physician now has something to prescribe for a disease that previously had nothing approved, and whether the drug changes the part of the disease that families notice most. The approval answers the first. The label is silent on the second, and whether the data gathered after approval fill that silence is what the next several years will show.
Emcitate will reach pharmacies in about two months. The answer will take longer.
Primary sources
- FDA, FDA Approves First Treatment for MCT8 Deficiency, Sept. 28, 2026, for the approval, the indication, the mechanism, the regulatory designations and the FDA quotation.
- Pharmacy Times, FDA Approves Tiratricol, First Treatment for MCT8 Deficiency, Sept. 29, 2026, for the ReTRIACt design and results, the 12-month open-label data, the assay cross-reactivity and monitoring instruction, the dosing, preparation, interaction and storage instructions, the adverse reaction list, the availability timeline and the median life expectancy figure reported by Egetis.
- Contemporary Pediatrics, FDA approves tiratricol as first treatment for peripheral thyrotoxicosis in MCT8 deficiency, Sept. 29, 2026, for the scope of the indication and the disease description.
- American Thyroid Association, ATA Supports FDA Warning on Triax, Feb. 26, 2000, for the November 1999 FDA warning, TRIAC's potency relative to thyroxine, the dose equivalence, the organs named as more sensitive and the conclusion on weight loss.
- Placera, Pareto: Egetis FDA-godkannande var vantat, Sept. 29, 2026, for the analyst's assessment, the label comparison, the U.S. patient estimates, the German sales observation and the voucher plan.